Free Trial

Synaptogenix (SNPX) Competitors

Synaptogenix logo
$2.20 -0.10 (-4.35%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SNPX vs. ERNA, TRIB, EQ, GELS, NKGN, ME, RLMD, MRKR, SYBX, and NXTC

Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Eterna Therapeutics (ERNA), Trinity Biotech (TRIB), Equillium (EQ), Gelteq (GELS), NKGen Biotech (NKGN), 23andMe (ME), Relmada Therapeutics (RLMD), Marker Therapeutics (MRKR), Synlogic (SYBX), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

Synaptogenix vs.

Synaptogenix (NASDAQ:SNPX) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.

Synaptogenix has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. Eterna Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -42.14% -29.42%
Eterna Therapeutics -7,513.88%N/A -117.48%

Synaptogenix currently has a consensus price target of $14.00, indicating a potential upside of 533.48%. Given Synaptogenix's stronger consensus rating and higher probable upside, equities analysts clearly believe Synaptogenix is more favorable than Eterna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Eterna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Synaptogenix's average media sentiment score of 1.38 beat Eterna Therapeutics' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company Overall Sentiment
Synaptogenix Positive
Eterna Therapeutics Neutral

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Synaptogenix received 2 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
SynaptogenixOutperform Votes
2
66.67%
Underperform Votes
1
33.33%
Eterna TherapeuticsN/AN/A

Synaptogenix has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 5.61, suggesting that its share price is 461% more volatile than the S&P 500.

Synaptogenix has higher earnings, but lower revenue than Eterna Therapeutics. Synaptogenix is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynaptogenixN/AN/A-$6.04M-$10.08-0.22
Eterna Therapeutics$535K26.62-$21.67M-$8.31-0.03

Summary

Synaptogenix beats Eterna Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNPX vs. The Competition

MetricSynaptogenixPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.07M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.229.0626.7119.71
Price / SalesN/A251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book0.096.456.774.50
Net Income-$6.04M$143.98M$3.23B$248.22M
7 Day Performance-0.45%2.41%1.80%0.56%
1 Month Performance3.71%4.56%11.10%13.17%
1 Year Performance-54.24%-2.67%17.11%7.30%

Synaptogenix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNPX
Synaptogenix
2.177 of 5 stars
$2.21
-3.9%
$14.00
+533.5%
-54.2%$3.07MN/A-0.224Positive News
Earnings Report
Gap Up
ERNA
Eterna Therapeutics
0.7774 of 5 stars
$0.22
+4.3%
N/A-88.9%$13.66M$582,000.00-0.0310Gap Up
TRIB
Trinity Biotech
0.735 of 5 stars
$0.76
+3.6%
N/A-49.9%$13.66M$59.13M-0.33480
EQ
Equillium
2.6324 of 5 stars
$0.38
-0.5%
$3.00
+685.1%
-74.5%$13.65M$41.10M-2.7340
GELS
Gelteq
N/A$1.44
flat
N/AN/A$13.59MN/A0.00N/APositive News
NKGN
NKGen Biotech
N/A$0.30
+11.1%
N/A-85.8%$13.48M$80,000.00-0.06N/APositive News
Gap Up
ME
23andMe
N/A$0.50
-35.3%
N/A-95.3%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
RLMD
Relmada Therapeutics
4.431 of 5 stars
$0.39
-2.1%
$4.25
+989.7%
-84.0%$12.95MN/A-0.1410Positive News
Insider Trade
Gap Down
MRKR
Marker Therapeutics
4.1018 of 5 stars
$1.14
flat
$13.17
+1,055.0%
-72.5%$12.90M$6.59M-0.9560Positive News
Analyst Revision
Gap Up
SYBX
Synlogic
N/A$1.10
-2.2%
N/A-30.9%$12.87M$8,000.00-0.2680Upcoming Earnings
NXTC
NextCure
3.9566 of 5 stars
$0.45
+3.3%
$3.50
+680.4%
-69.7%$12.58MN/A-0.2190

Related Companies and Tools


This page (NASDAQ:SNPX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners